Format

Send to

Choose Destination
J Clin Invest. 2013 Jul;123(7):2783-5. doi: 10.1172/JCI69070. Epub 2013 Jun 17.

Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming.

Author information

1
University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA. hff@virginia.edu

Abstract

Adenoid cystic carcinoma (ACC), a relatively rare malignancy usually of salivary gland origin, has a signature v-myb avian myeloblastosis viral oncogene homolog-nuclear factor I/B (MYB-NFIB) gene fusion that activates MYB transcriptional regulatory activity. A new study in this issue by Stephens et al. is a comprehensive genomic mutation profiling analysis of this neoplasm and documents a common theme of alteration in chromatin regulatory genes. Also, mutations in SPEN (split ends, homolog of Drosophila), which encodes an RNA-binding coregulatory protein, suggest that other changes in transcriptional regulation may involve the NOTCH, FGFR, or other signaling pathways in which SPEN participates. Since there is a low prevalence of mutations in common oncogenes and tumor-suppressor genes, it is likely that alterations primarily in specific transcriptional regulatory genes, augmented by changes in chromatin structure, drive the neoplastic process in ACC.

PMID:
23778135
PMCID:
PMC3696562
DOI:
10.1172/JCI69070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center